Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS001 (Toripalimab) plus Nab-Paclitaxel in TNBC
NCT03777579Phase 3Suspended
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Dec 2018; status: suspended.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03777579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777579.